Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical Infectious Diseases

• Publication date

  2018-07-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/cid/ciy129PMID 29471432
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term Impact of a “3 + 0” Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002–2014

  2017cited by this paper
• Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany

  2016cited by this paper
• Invasive pneumococcal disease in Australia, 2011 and 2012.

  2016cited by this paper
• Vaccine effectiveness of PCV13 in a 3+1 vaccination schedule.

  2016cited by this paper
• Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden

  2016cited by this paper
• Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study.

  2016cited by this paper
• Australian vaccine preventable disease epidemiological review series: Influenza 2006 to 2015.

  2016cited by this paper
• Why we need pneumococcal vaccine effectiveness studies.

  2016cited by this paper
• Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

  2015cited by this paper
• Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.

  2015cited by this paper
• Long term population impact of seven-valent pneumococcal conjugate vaccine with a "3+0″ schedule-How do "2+1″ and "3+1″ schedules compare?

  2015cited by this paper
• Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.

  2015cited by this paper
• Invasive pneumococcal disease in Australia, 2009 and 2010.

  2015cited by this paper
• Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study.

  2014cited by this paper
• Trends in Asymptomatic Nasopharyngeal Colonization With Streptococcus pneumoniae After Introduction of the 13-valent Pneumococcal Conjugate Vaccine in Calgary, Canada

  2014cited by this paper
• Duration of Protection After First Dose of Acellular Pertussis Vaccine in Infants

  2014cited by this paper
• Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.

  2013cited by this paper
• Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

  2013cited by this paper
• Pneumococcal vaccines WHO position paper--2012.

  2012cited by this paper
• Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period.

  2012cited by this paper
• Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis.

  2011cited by this paper
• Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.

  2011cited by this paper
• Contribution of vaccines to our understanding of pneumococcal disease

  2011cited by this paper
• Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.

  2011cited by this paper
• Using the Indirect Cohort Design to Estimate the Effectiveness of the Seven Valent Pneumococcal Conjugate Vaccine in England and Wales

  2011cited by this paper
• Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers

  2010cited by this paper
• Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers

  2010cited by this paper
• The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes.

  2010cited by this paper
• The Australian Childhood Immunisation Register-A model for universal immunisation registers?

  2009cited by this paper
• Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.

  2009cited by this paper
• Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial.

  2007cited by this paper
• Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.

  2006cited by this paper
• Epidemiological differences among pneumococcal serotypes.

  2005cited by this paper
• Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

  2003cited by this paper
• The Australian Immunisation Handbook

  2000cited by this paper
• Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

  2000cited by this paper
• Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine.

  1980cited by this paper
• Pneumococcal Disease after Pneumococcal Vaccination

  1980cited by this paper

• Effect of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in rural Gambia 10 years after its introduction: A population-based cross-sectional study.

  2025cites this paper
• Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review

  2025cites this paper
• Effect of pneumococcal conjugate vaccine booster dose on prevention of invasive pneumococcal disease in British Columbia, 2003-2018.

  2025cites this paper
• Effectiveness of vaccine dosing schedules for pneumococcal invasive disease in children: A systematic review and meta-analysis

  2025cites this paper
• Effectiveness of a Single Dose of Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Children: A Systematic Literature Review

  2025cites this paper
• Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development

  2024cites this paper
• Consenso de la Asociación Mexicana de Infectología Pediátrica (AMIP): sobre el impacto de la vacunación en la disminución de la carga de enfermedad neumocócica en México, 2024

  2024cites this paper
• Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study.

  2024cites this paper
• Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational Study.

  2024cites this paper
• Serotype epidemiology and antibiotic resistance of pneumococcal isolates colonizing infants in Botswana (2016–2019)

  2024cites this paper
• Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance.

  2024cites this paper
• Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (SynflorixTM and Prevenar13TM)) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-labelled randomized controlled trial in Indian children.

  2023cites this paper
• Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.

  2023cites this paper
• Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.

  2022cites this paper
• Validation of Fourier Transform Infrared Spectroscopy for Serotyping of Streptococcus pneumoniae

  2022cites this paper
• Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana.

  2022cites this paper
• PCV13 Pediatric Routine Schedule Completion and Adherence Before and During the COVID-19 Pandemic in the United States

  2022cites this paper
• Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data

  2022cites this paper
• SYSTEMATIC REVIEW A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children

  2022influential citation
• Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study.

  2022cites this paper
• The incremental burden of invasive pneumococcal disease associated with a decline in childhood vaccination using a dynamic transmission model in Japan: A secondary impact of COVID-19

  2021cites this paper
• Pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: a retrospective record linkage cohort study

  2021cites this paper
• Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study

  2021cites this paper
• Impact of 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage Rates of Streptococcus pneumoniae in a Rural Community in the Dominican Republic

  2021cites this paper
• Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys

  2021cites this paper
• Pneumococcal Immunization Strategies for High-Risk Pediatric Populations Worldwide: One Size Does Not Fit All

  2021cites this paper
• Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease

  2021cites this paper
• Pneumococcal vaccine implementation in the African meningitis belt countries: the emerging need for alternative strategies

  2021cites this paper
• Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial

  2020cites this paper
• Changing Epidemiology and Predisposing Factors for Invasive Pneumococcal Disease at Two Australian Tertiary Hospitals.

  2020cites this paper
• Australian vaccine preventable disease epidemiological review series: invasive Haemophilus influenzae type b disease, 2000-2017.

  2020cites this paper
• Persistence of immunity in children immunised with 13-valent pneumococcal conjugate vaccine and impact on nasopharyngeal carriage: a cross-sectional study

  2020cites this paper
• Effect of Haemophilus influenzae type b and 13-valent pneumococcal conjugate vaccines on childhood pneumonia hospitalizations and deaths in Botswana.

  2020cites this paper
• Where do we Stand After PCV13 Vaccine Introduction?

  2020cites this paper
• Epidemiologic Benefits of Pneumococcal Vaccine Introduction into Preventive Vaccination Programs.

  2020cites this paper
• Effect of 10-Valent Pneumococcal Conjugate Vaccine on Streptococcus pneumoniae Nasopharyngeal Carriage Among Children Less Than 5 Years Old: 3 Years Post-10-Valent Pneumococcal Conjugate Vaccine Introduction in Mozambique.

  2020cites this paper
• Post-Vaccination Streptococcus pneumoniae Carriage and Virulence Gene Distribution among Children Less Than Five Years of Age, Cape Coast, Ghana

  2020influential citation
• Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study

  2020cites this paper
• Persistence of pneumococcal antibodies after primary immunisation with a polysaccharide–protein conjugate vaccine

  2019cites this paper
• The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology.

  2019cites this paper
• Rotavirus Epidemiology and Monovalent Rotavirus Vaccine Effectiveness in Australia: 2010–2017

  2019cites this paper
• Using pneumococcal carriage studies to monitor vaccine impact in low- and middle-income countries.

  2019cites this paper
• To boost or not to boost? Lessons from the Australian pneumococcal conjugate vaccination program.

  2019cites this paper
• A National Review of Vaccine Preventable Diseases in Australia

  2019cites this paper
• Smart Scheduling - optimising national immunisation programmes to achieve maximum impact.

  2019cites this paper
• Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions

  2019cites this paper
• Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study

  2019cites this paper
• Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.

  2018cites this paper
• Examining Duration of Protection: Should a Booster Dose Be Part of All Infant Pneumococcal Conjugate Vaccine Programs?

  2018cites this paper